secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inozyme Pharma, Inc. (—)
CIK:        0001693011
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001193125-25-153582
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin completes acquisition of Inozyme for $4.00 per share; Inozyme to delist
--------------------------------------------------------------------------------

- BioMarin completed tender offer acquiring 69.8% of Inozyme shares at $4.00/share cash; subsequent merger completed July 1, 2025.
- Inozyme will delist from Nasdaq and deregister under Exchange Act; Form 15 to be filed.
- All Inozyme directors resigned; G. Eric Davis, Eric Fleekop, Brian Mueller appointed to board.
- Executive officers resigned; G. Eric Davis became President, Eric Fleekop became Secretary.
- In-the-money stock options and RSUs accelerated and cashed out at $4.00/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1693011/000119312525153582/0001193125-25-153582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1693011/000119312525153582/d90696d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-153582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer